Member Info for 13thmonkey

And they are still able to remain on treatment.

You've been patient?

Up until a few months ago he struggled with getting some of the details right

No FAP until they settle and start to grow a protective stroma etc.

As for the shrinking tumour problem, it's a surface to volume ratio problem, When very large there is much more volume per unit of surface area, and the volume is where growth comes from and nutrients are taken up from the blood supply etc. So as you shrink it and the surface area reduces the absolute volume reduces quicker, so there's less and less for the tumour to work with. I don't see it being a problem.

Not a medical opinion, just an engineer doing some sums.

Crypto given that formal offers are generally preceded by informal offers that could easily be rebuffed then we won't have heard much.

Rorke, you know full well that the extension of the trials was to do with it performing such that there was no sign of the mtd and has nothing to do with the patents. So what's your aim here?

That F for that he's gone again, and with his usual plethora of insults and put downs.

Did you forget the non dilutitive comment.

You'll obviously do P2 before P3, and so if P2 shows efficacy in a small group then because this is a known drug they would allow it to be used live. If it were not a known drug they'd want P3 which is many more patients to understand longer term consequences.

They may choose to shorten P2 if the results are good enough. Orphan programmes may allow for this.

Additionally for some STS dox is a known treatment but can only be used in a limited number of doses.

Alan has said that ph2 is pivotal and enough to start usage outside of trials. They may be a ph3 in parallel with usage.

Robin, if the jam was already here the case for investment is gone as the growth will have happened. Jam tomorrow = potential for growth, Jam in the jar = growth has occurred, by which point you are too late.

But it's Jim Cramer, a counter indicator to himself.

Is there even a physical location? I don't think there is.

I'm sure I've seen a big table showing reduced instances of side effects. I'm sorry convinced that this is the same days that you were whining about not being shown, obviously before something is released you've not seen it, but that seemed to be a difficult concept. Lower side effects equals a minimal impact of other fap locations, it's not perfect but it's a lot better than straight dox and maybe than many other chemos.

I've no idea, seems oddly specific a person to impersonate. And seems at odds with behaviour here (I think).

It's this you? https://twitter.com/Capitelize/status/1725488755761398063?t=XBgaWR9LU8b2OEAph_jHCg&s=19

BV, I'm not sure that the link between FAP and being susceptible to Doxy is necessarily true. The patients were chosen for FAP-Alpha and doxy (and similar) naïve which tends to infer it's not the standard treatment, and therefore their cancers may not be susceptible, or there is better available.

However, and I've suggested this before as I'm sure others have, given that doxy is so destructive to tissues (see the injection site issues) I think it's quite likely that with the right dosage it'll do something if it's in the right place.

Oh experienced one, it will always be based on mcap as the SP can be influenced by other actions. We could have an SP of £140 easily if we did a 100:1 reading of the issued shares and nothing will have changed at all.

At least now that American virtual cloud technologies has gone the experienced investor won't be looking at the wrong ticker.

How many have received the active element? A million?

Based on no knowledge, yes. It would have been advertised by now unless they are expecting the circumstances to undo themselves and then original candidate to start later.